Endometrial Changes Associated with Mifepristone: A Review.

Area of Science:

• Reproductive Medicine
• Endocrinology
• Gynecologic Pathology

Background:

• Mifepristone, a progesterone receptor modulator, is used in gynecology and other conditions.
• Progesterone receptor modulator-associated endometrial changes (PAECs) are increasing and mimic endometrial hyperplasia or carcinoma.
• The molecular mechanisms of PAECs are not fully understood, but hormonal influences are suspected.

Purpose of the Study:

• To investigate the safety and implications of mifepristone use, particularly regarding endometrial changes.
• To explore potential risk factors and preventive strategies for PAECs.

Main Methods:

• Review of clinical data and histological findings related to mifepristone use.
• Analysis of hormonal influences and endometrial responses.
• Assessment of safety profiles for low-dose mifepristone regimens.

Main Results:

• Low-dose mifepristone (≤10 mg/d) in young women during the early follicular phase appears safe.
• Histological heterogeneity exists between ectopic and eutopic endometrium.
• Estradiol (E2) monitoring is advised before treatment.

Conclusions:

• While mifepristone has expanding applications, PAECs are an emerging concern.
• Risk assessment and preventive strategies like intermittent treatment, ultrasound, and LNG-IUS are recommended.
• Careful patient selection and monitoring are crucial for safe mifepristone management.